FLT3 and acute myeloid leukemia: In phase I/II trials recruited elderly AML patients with FLT3 mutations, sunitinib in combination with intensive chemotherapy demonstrated a complete remission/complete remission with incomplete hematological recovery (CR/CRi) rate of 59% with relapse-free survival of 1 year.